Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension

Malaria Clinical Trial

Official title:

Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension. - A Single Oral Dose Study to Investigate Pharmacokinetics of Atovaquone and Proguanil From Combination Tablets and Atovaquone From Atovaquone Suspension in Japanese Healthy Males. -

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01858831
• Other study ID #: 116441
• Status: Completed
• Phase: Phase 1
• First received: March 15, 2012
• Last updated: March 21, 2017
• Start date: April 2012
• Est. completion date: May 2012

Study information

• Verified date: March 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be a single-center, phase I, randomized, open, in fed condition, parallel, single dose study to evaluate the pharmacokinetics and the safety, tolerability of Atovaquone/proguanil combination tablets and atovaquone suspension in Japanese healthy male subjects.

Serial blood samples will be collected for the determination of the plasma concentration of atovaquone, proguanil and cycloguanil after dosing of atovaquone 1000mg/proguanil 400 mg and the plasma atovaquone concentration of atovaquone 750 and 1500 mg. Safety assessments will be performed for each treatment group.

CYP2C19 contribute to proguanil metabolism. CYP2C19 genotype will be determined in atovaquone/proguanil dosing group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: May 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy as defined as being free from clinically significant illness or disease as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, vital sign, laboratory tests and ECG.

• Japanese healthy male between 20 and 55 years of age inclusive, at the time of signing the informed consent.

• Body weight => 50 kg and BMI within the range 18.5- 25 kg/m2

• Non-smoker or ex-smoker having ceased smoking for at least 6 months. (inclusive).

• ALT, alkaline phosphatase and bilirubin below the upper limit of normal (ULN)

• Single QTcB< 450 msec.

• Vital sign within the following ranges; Systolic blood pressure: < 90 mmHg or > 140 mmHg, Diastolic blood pressure: < 45 mmHg or > 90 mmHg, Plus rate: < 45 bpm or > 100 bpm, Body temperature: 37.5 C

• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

• A positive results of syphilis, HBs antigen, HCV antibody, HIV antibody and HTLV-1 antibody at the time of screening.

• History of any cardiac diseases irrespective of with or without symptom.

• An episode of cardiac syncope within one year before screening period.

• History/evidence of clinically significant pulmonary diseases and hyper/hypo-thyroidism.

• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

• A positive pre-study drug screen.

• History of regular alcohol consumption exceeding, on average, 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 350 mL of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits) within 6 months of screening.

• The subject had participated in a clinical study or post-marketing study with an investigational or a non-investigational product during the previous 4 months preceding the administration of study medication of this study.

• The subject had participated in a clinical study or post-marketing study with an investigational or a non-investigational product during the previous 4 months preceding the administration of study medication of this study.

• Exposure to more than four new chemical entities within 12 months prior to the first dosing day.

• Unable to refrain from the use of alcohol, prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.

• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy excluding pollen allergy without current symptoms.

• Where participation in the study would result in donation of blood or blood products in excess of 400 mL within a 4 month or 200 mL within 2 month.

• Unwillingness or inability to follow the procedures outlined in the protocol.

• Subject is mentally or legally incapacitated.

Related Conditions & MeSH terms

• Malaria

Intervention

Drug:
• Atovaquone/proguanil HCL
Atovaquone/proguanil HCL
• Atovaquone
Atovaquone

Locations

Country	Name	City	State
Japan	GSK Investigational Site	Kagoshima

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	plasma atovaquone concentration		pre, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168, 216, 336 post dose
Primary	plasma proguanil concentration		pre, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168, 216, 336 post dose
Primary	plasma cycloguanil concentration		pre, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168, 216, 336 post dose
Secondary	Number of participants with adverse events		up to 336h post dose
Secondary	Change in Systolic Blood Pressure	Change values at 4, 24, 72, 168 and 336 h post-dose from baseline (pre-dose)	at pre-dose, 4, 24, 72, 168 and 336 h post-dose
Secondary	Change in ECG findings	Change at 4, 72, 168 and 336 h post-dose from baseline (pre-dose)	at pre-dose, 4, 72, 168 and 336 h post-dose
Secondary	Laboratory	Change values at 72, 168 and 336 h post-dose from baseline (pre-dose)	at pre-dose, 72, 168 and 336 h post-dose
Secondary	Change in Diastolic Blood Pressure	Change values at 4, 24, 72, 168 and 336 h post-dose from baseline (pre-dose)	at pre-dose, 4, 24, 72, 168 and 336 h post-dose
Secondary	Change in Heart rate	Change values at 4, 24, 72, 168 and 336 h post-dose from baseline (pre-dose)	at pre-dose, 4, 24, 72, 168 and 336 h post-dose
Secondary	Change in Hematology values	Change values at 72, 168 and 336 h post-dose from baseline (pre-dose)	at pre-dose, 72, 168 and 336 h post-dose
Secondary	Change in Biochemistry values	Change values at 72, 168 and 336 h post-dose from baseline (pre-dose)	at pre-dose, 72, 168 and 336 h post-dose
Secondary	Change in Urinalysis values	Change values at 72, 168 and 336 h post-dose from baseline (pre-dose)	at pre-dose, 72, 168 and 336 h post-dose

External Links

•   Results for study 116441 can be found on the GSK Clinical Study Register.